Desmoid Tumor, NOTCH Gene Mutation Positive Tumors
Conditions
Keywords
desmoid tumor, aggressive fibromatosis, desmoid fibromatosis, Notch-positive tumors
Brief summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Interventions
DRUGNirogacestat (Gamma Secretase Inhibitor)
Patients will receive nirogacestat tablets to be taken orally.
Sponsors
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.
Contacts
CONTACTUS Medical Information
Outcome results
None listed